Immune system

Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

Thursday, April 2, 2020 - 1:30pm

Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA).

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA).
  • Kite and Teneobio will also collaborate on the discovery of antibodies directed to four additional targets, using Teneobios proprietary Human Heavy-Chain Antibodies (UniAb) platform, to be used in CAR T cell therapies for multiple myeloma and other cancers.
  • Kite is committed to pursuing novel CAR T therapies that have the potential to be meaningfully differentiated treatment options for people living with multiple myeloma, said Peter Emtage, PhD, Senior Vice President of Research at Kite.
  • All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.

ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services

Thursday, April 2, 2020 - 11:31am

ERS Genomics Limited (ERS Genomics), which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Axxam S.p.A. (Axxam), a leading discovery biology company, today announced the signing of a license agreement granting Axxam access to ERS Genomics' CRISPR-Cas9 patent portfolio, to support Axxam's integrated discovery service platform.

Key Points: 
  • ERS Genomics Limited (ERS Genomics), which was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Axxam S.p.A. (Axxam), a leading discovery biology company, today announced the signing of a license agreement granting Axxam access to ERS Genomics' CRISPR-Cas9 patent portfolio, to support Axxam's integrated discovery service platform.
  • The platform will applied across Axxams integrated discovery services, in fields such as pharmaceuticals, crop protection, animal health, and food and beverages.
  • We are proud to add Axxam to our growing list of partners applying CRISPR-Cas9 technology to their service offerings, said Eric Rhodes, CEO of ERS Genomics.
  • Axxam's discovery services cover a wide array of fields and we look forward to seeing how its use of CRISPR-Cas9 impacts these areas."

Global Immune Checkpoint Inhibitors Market Outlook 2022

Wednesday, April 1, 2020 - 7:15pm

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 1, 2020 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
  • According to the report Global Immune Checkpoint Inhibitors Market Outlook 2022, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022.
  • In addition, the report also highlights various opportunities available for the growth of the global immune checkpoint inhibitors market.
  • On the basis of the type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

Wednesday, April 1, 2020 - 1:30pm

SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences.
  • Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
  • Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stagebiotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (AlloCAR T) therapies for cancer.
  • Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Global Food Allergen Testing Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com

Wednesday, April 1, 2020 - 10:50am

The "Food Allergen Testing - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Food Allergen Testing - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Food Allergen Testing market worldwide is projected to grow by US$317.5 Million, driven by a compounded growth of 6.5%.
  • Peanut & Soy, one of the segments analyzed and sized in this study, displays the potential to grow at over 8%.
  • Poised to reach over US$278 Million by the year 2025, Peanut & Soy will bring in healthy gains adding significant momentum to global growth.

Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19

Tuesday, March 31, 2020 - 9:39pm

Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S.

Key Points: 
  • Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S.
    Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs.
  • We were even more pleased to see how capable the antibodies were in blocking the virus that causes COVID-19.
  • Ten ostriches have been vaccinated, and the antibodies from their eggs have already been used in masks, nasal drops, and candies in Japan.
  • According to Ostrich Pharma USA Co-CEO Stuart Greenberg, We recognize the enormous need for multiple approaches to the COVID-19 pandemic in the US.

SAB Biotherapeutics Awarded $27M Contract to Develop Novel Rapid Response Capability for U.S. Department of Defense

Tuesday, March 31, 2020 - 3:44pm

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.

Key Points: 
  • SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, advancing a new class of immunotherapies leveraging the native human immune response, announced today it has been awarded a contract from the U.S. Department of Defense (DoD) to develop and test a Rapid Response Antibody Program, valued at up to $27 million.
  • View the full release here: https://www.businesswire.com/news/home/20200331005569/en/
    SAB Biotherapeutics has a unique ability to rapidly respond to emerging threats with its proprietary human polyclonal therapeutic platform.
  • Driven by advanced genetic engineering and antibody science, SAB has developed the DiversitAb platform to naturally and rapidly produce large amounts of targeted human antibodies, without human donors.
  • Our therapies leverage the native immune response thereby providing a highly-specific match against the complexity, diversity and mutation of disease.

Primmune Therapeutics Announces the Selection of PRTX007 as Its Clinical Development Candidate for COVID-19 and Oncology Indications

Tuesday, March 31, 2020 - 1:00pm

SAN DIEGO, March 31, 2020 /PRNewswire/ -- Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications.

Key Points: 
  • SAN DIEGO, March 31, 2020 /PRNewswire/ -- Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications.
  • "PRTX007 is an oral small molecule that specifically activates toll-like receptor 7 ("TLR7") which drives the innate immune system's primary response to viral infections," said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics.
  • "PRTX007 was derived from Primmune's extensive TLR7 agonist discovery program and has demonstrated sustained dose-dependent innate immune induction in vivo without the production of inflammatory cytokines, such as IL-6 or TNF alpha.
  • "Since PRTX007 stimulates your natural antiviral innate immune response, we believe it has potential utility as a prophylaxis, first-line defense against SARS-CoV-2, SARS-CoV-2 mutants, and future novel pathogens."

Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

Tuesday, March 31, 2020 - 12:33pm

"Being able to rapidly develop novel COVID-19 therapies highlights core attributes of Kleo's platform technology namely speed and modularity," said Doug Manion, MD, CEO of Kleo Pharmaceuticals.

Key Points: 
  • "Being able to rapidly develop novel COVID-19 therapies highlights core attributes of Kleo's platform technology namely speed and modularity," said Doug Manion, MD, CEO of Kleo Pharmaceuticals.
  • We bear a responsibility to advance our anti-COVID-19 program as rapidly as possible to determine its utility in the fight.
  • Kleo's ARM technology platform can rapidly develop fully synthetic bifunctional molecules that redirect a patient's own antibodies for therapeutic effect.
  • Green Cross LabCell (GCLC)is a cell therapy-specialized company focusing on NK cell and stem cell therapeutics.

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

Tuesday, March 31, 2020 - 12:30pm

This therapeutic approach results in highly targeted editing of the HSCs DNA to induce fetal hemoglobin (HbF) expression.

Key Points: 
  • This therapeutic approach results in highly targeted editing of the HSCs DNA to induce fetal hemoglobin (HbF) expression.
  • The edited cells are returned to the patient, where the expression of HbF is expected to reduce the deleterious effects of sickle hemoglobin (HbS).
  • Novartis IND application triggered a milestone payment to Intellia, and the company is eligible to receive additional downstream success-based milestones and royalties.
  • Intellia looks forward to Novartis efforts to advance other targets that were selected to develop as additional CRISPR/Cas9-based cell therapy products.